DNA损伤修复相关通路的合成致死靶点研究及其在卵巢癌中的应用和前景

Study on Synthetic Lethal Target of DNA Damage Repair Related Pathways and Its Application and Prospect in Ovarian Cancer

DNA损伤引发细胞启动一系列DNA损伤应答(DNA damage response,DDR),包括DNA损伤修复、细胞周期检查点激活、细胞周期阻滞、各种细胞内信号转导途径的活化和细胞凋亡等。DNA损伤修复(DNA damage repair)是细胞维持基因组稳定性的重要机制,于2015年获得诺贝尔化学奖。DNA损伤修复途径主要包括:碱基切除修复(base-excision repair,BER)、核苷酸切除修复(nucleotide excision repair,NER)、错配修复(mismatch repair,MMR)、同源重组(homologous recombination,HR)和非同源末端连接(non-homologous end joining,NHEJ)等,分别在DNA单链断裂(single-strand break,SSB)或双链断裂(double-strand break,DSB)等损伤修复中发挥重要作用。DNA损伤修复缺陷与肿瘤发生发展密切相关,同时也是肿瘤治疗的重要靶点。DNA损伤修复通路的多聚ADP核糖聚合酶(poly-ADP-ribose polymerase,PARP)与乳腺癌易感基因BRCA 1/2等存在合成致死(synthetic lethality)作用,使PARP抑制剂(PARP inhibitor,PARPi)成为第一个也是目前唯一上市的肿瘤治疗合成致死靶药。PARPi在卵巢癌及多种实体瘤治疗中疗效良好,使DNA损伤修复及相关DDR通路的合成致死靶药研发成为热点,其他在研靶点主要包括:共济失调毛细血管扩张突变蛋白(ataxia telangiectasia-mutated protein,ATM)、共济失调毛细血管扩张与RAD3相关蛋白(ataxia telangiectasia and Rad3 related protein,ATR)、DNA依赖性蛋白质激酶催化亚单位(DNA-dependent protein kinase catalytic subunit,DNA-PKcs)、细胞周期检测点激酶1(checkpoint kinase1,CHK1)、细胞周期检测点激酶2(checkpoint kinase 2,CHK2)、阻止有丝分裂的蛋白质激酶WEE1等。PARPi与其他DDR靶药、抗血管生成药物及免疫检查点抑制剂的联用,有可能成为克服PARPi耐药、提高疗效的有效手段和发展前景。本文针对DNA损伤修复及相关DDR通路的关键分子和潜在肿瘤治疗靶点进行综述,阐述了DNA损伤修复相关通路的合成致死靶点研究及在卵巢癌的应用和前景,为基础研究及临床应用提供指导。

DNA damage triggers cells to initiate a series of DNA damage response(DDR),including DNA damage repair,cell cycle checkpoint activation,cell cycle arrest,activation of various intracellular signal transduction pathways,and cell apoptosis,etc.DNA Damage Repair,an important mechanism by which cells maintain genomic stability,was awarded the Nobel Prize in Chemistry in 2015.DNA damage repair pathways mainly include:base-excision repair(BER),nucleotide excision repair(NER),mismatch repair(MMR),homologous recombination(HR)and non-homologous end joining(NHEJ).They play an important role in the repair of DNA damage such as single-strand break(SSB)or double-strand break(DSB).DNA damage repair defects are closely related to tumorigenesis and development and is also an important target for tumor therapy.Poly-ADP-ribose polymerase(PARP)and breast cancer susceptibility gene BRCA1/2 and others in the DNA damage repair pathways have synthetic lethality effects.It makes PARP inhibitor(PARPi)be the first and currently the only commercially available synthetic lethal target drug for tumor therapy.PARPi has good efficacy in the treatment of ovarian cancer and a variety of solid tumors,which make the research and development of synthetic lethal target drugs related to DNA damage repair and DDR pathway become a hot spot.Other targets under research mainly include:ataxia telangiectasia-mutated protein(ATM),ataxia telangiectasia and RAD3 related protein(ATR),DNA-dependent protein kinase catalytic subunit(DNA-PKcs),checkpoint kinase1(CHK1),Checkpoint kinase 2(CHK2),mitogen-preventing protein kinase WEE1,etc.The combination of PARPi with other DDR target drugs,anti-angiogenesis drugs or immune checkpoint inhibitors may become effective means and development prospect to overcome PARPi resistance and improve the therapeutic effect.Here we review the key molecules and potential tumor therapeutic targets in DNA damage repair and related DDR pathways,and the research on synthetic lethal targets and their application and prospect in ovarian cancer.We aim to provide guidance for basic research and clinical application.